Articles with public access mandates - Su-Pin chooLearn more
Not available anywhere: 4
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial
D Tai, K Loke, A Gogna, NA Kaya, SH Tan, T Hennedige, D Ng, F Irani, ...
The Lancet Gastroenterology & Hepatology 6 (12), 1025-1035, 2021
Mandates: Chinese Academy of Sciences, National Natural Science Foundation of China …
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma
SF Ang, SH Tan, HC Toh, DYH Poon, SYK Ong, KF Foo, SP Choo
American Journal of Clinical Oncology 35 (3), 222-227, 2012
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Comparison of health state values derived from patients and individuals from the general population
M Gandhi, RS Tan, R Ng, SP Choo, WK Chia, CK Toh, C Lam, PT Lee, ...
Quality of Life Research 26, 3353-3363, 2017
Mandates: A*Star, Singapore, Ministry of Health, Singapore
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects
M Ng, S Chen, WS Ong, A Balachander, A Seet, J Yeong, N Sutiman, ...
International Journal of Cancer 151 (3), 435-449, 2022
Mandates: National Medical Research Council, Singapore
Available somewhere: 41
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...
The Lancet 389 (10088), 2492-2502, 2017
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma
A Jusakul, I Cutcutache, CH Yong, JQ Lim, MN Huang, N Padmanabhan, ...
Cancer discovery 7 (10), 1116-1135, 2017
Mandates: US Department of Energy, US National Institutes of Health, National Natural …
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ...
Journal of Clinical Oncology 36 (3), 276-282, 2018
Mandates: US National Institutes of Health
First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
RD Kim, D Sarker, T Meyer, T Yau, T Macarulla, JW Park, SP Choo, ...
Cancer discovery 9 (12), 1696-1707, 2019
Mandates: Cancer Research UK, National Institute for Health Research, UK
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma
W Zhai, TKH Lim, T Zhang, ST Phang, Z Tiang, P Guan, MH Ng, JQ Lim, ...
Nature communications 8 (1), 4565, 2017
Mandates: National Medical Research Council, Singapore
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery
SB Ng, C Chua, M Ng, A Gan, PSY Poon, M Teo, C Fu, WQ Leow, KH Lim, ...
Scientific reports 7 (1), 40737, 2017
Mandates: A*Star, Singapore, National Medical Research Council, Singapore
Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in Opisthorchis viverrini associated cholangiocarcinoma
KR Chng, SH Chan, AHQ Ng, C Li, A Jusakul, D Bertrand, A Wilm, ...
EBioMedicine 8, 195-202, 2016
Mandates: US National Institutes of Health, A*Star, Singapore, National Medical …
Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond
YH Lee, D Tai, C Yip, SP Choo, V Chew
Frontiers in immunology 11, 568759, 2020
Mandates: National Medical Research Council, Singapore
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
HHM Ng, RY Lee, S Goh, ISY Tay, X Lim, B Lee, V Chew, H Li, B Tan, ...
Journal for immunotherapy of cancer 8 (2), 2020
Mandates: US National Institutes of Health, National Medical Research Council, Singapore
Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine–induced hand-foot syndrome: a randomized clinical trial
YS Yap, LL Kwok, N Syn, WY Chay, JWK Chia, CK Tham, NS Wong, ...
JAMA oncology 3 (11), 1538-1545, 2017
Mandates: National Research Foundation, Singapore
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma
Y Cheng, B Gunasegaran, HD Singh, CA Dutertre, CY Loh, JQ Lim, ...
Immunity 54 (8), 1825-1840. e7, 2021
Mandates: A*Star, Singapore, National Medical Research Council, Singapore
Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma
JH Lam, HHM Ng, CJ Lim, XN Sim, F Malavasi, H Li, JJH Loh, K Sabai, ...
Frontiers in immunology 10, 2093, 2019
Mandates: US National Institutes of Health, National Medical Research Council, Singapore
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
WM Tai, WP Yong, C Lim, LS Low, CK Tham, TS Koh, QS Ng, WW Wang, ...
Annals of Oncology 27 (12), 2210-2215, 2016
Mandates: National Medical Research Council, Singapore
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
S Chuah, J Lee, Y Song, HD Kim, M Wasser, NA Kaya, K Bang, YJ Lee, ...
Journal of hepatology 77 (3), 683-694, 2022
Mandates: National Medical Research Council, Singapore
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
S Qin, SL Chan, W Sukeepaisarnjaroen, G Han, SP Choo, V Sriuranpong, ...
Therapeutic advances in medical oncology 11, 1758835919889001, 2019
Mandates: National Medical Research Council, Singapore
Publication and funding information is determined automatically by a computer program